Core Framework & Diagram The Future of Cancer Vaccines

Cancer vaccines are no longer only about prevention — they're becoming weapons of treatment

编辑部精选 · 照护框架与示意图

1

Preventive ALREADY HERE, MARKET-PROVEN

Vaccines that block cancer-causing viruses before infection ever happens — over 95% effective. Australia is on track to eliminate cervical cancer by 2028, the first cancer ever eliminated through vaccination.

2

Therapeutic PROOF OF CONCEPT, 2010

The first vaccine designed to treat existing cancer reached approval in 2010, proving the concept works — though the survival benefit was modest, since it targeted markers also found on healthy tissue.

3

Individualized mRNA Neoantigen THE 2023 BREAKTHROUGH

A vaccine built from a patient’s own unique tumor mutations, combined with standard immunotherapy, cut high-risk melanoma recurrence risk 44% in a major trial — with distant spread risk down 65%.

THE GOLDEN COMBINATION
A vaccine summons more soldiers (activating tumor-specific T cells); a checkpoint inhibitor removes their shackles (relieving suppression). Two different bottlenecks on the same chain — the combination outperforms either alone.

WHAT’S NEXT

The next frontier is prevention itself: vaccinating high-risk people before a tumor is even visible on a scan.
Expect adjuvant approval around 2025–2027, with Malaysia/Asia access following 3–8 years after US approval.

Frequently Asked Questions

When will individualized cancer vaccines be available in Asia?

mRNA-4157 is still in clinical trial stage, expected to first receive approval in the US around 2025–2027. Asia (China, Japan, Korea) usually follows one to three years after US approval; Malaysia may be later (three to five years). But clinical trial participation is a channel to access now — some institutions have channels for specific cancer patients to participate in clinical trials.

Will cancer vaccines attack normal cells?

Individualized neoantigen vaccines' core advantage is that neoantigens only exist in cancer cells (from tumor-specific somatic mutations), normal cells don't express these mutant proteins. Therefore, T cell responses targeting neoantigens theoretically have no aggressiveness toward normal tissue — higher safety than vaccines targeting TAAs (tumor-associated antigens, which normal tissue also expresses in small amounts).

I'm currently undergoing chemotherapy — can I also receive cancer vaccines?

Specific to the chemotherapy regimen and vaccine type. Chemotherapy may suppress the immune system, affecting vaccine response efficacy — during some chemotherapy regimens (especially highly myelosuppressive ones), vaccine effectiveness may be greatly reduced, and some live vaccines are contraindicated. mRNA vaccines are non-live vaccines, theoretically better safety profile, but optimal vaccination timing (like intervals between chemotherapy, or after chemotherapy completion) needs specific discussion with the attending oncologist.

'Cancer vaccine' and 'tumor vaccine' — are they the same thing?

In meaning, these two terms are often used interchangeably, but sometimes have subtle differences: 'cancer vaccine' more often refers to broader preventive or therapeutic vaccines, including virus-preventive ones like HPV; 'tumor vaccine' usually more specifically refers to therapeutic vaccines targeting tumor cells themselves. In clinical literature, neither has strictly unified usage — understand based on context.

Deep Read

Core Framework & Diagram The Future of Cancer Vaccines

1 Min Read The Future of Cancer Vaccines

The Future of Cancer Vaccines

1 Min Read The Future of Cancer Vaccines

The Future of Cancer Vaccines

Cancer vaccines are no longer only about prevention — they're becoming weapons of treatment

Related posts

Core Framework & Diagram How Does Sunlight Affect Immunity?

How Does Sunlight Affect Immunity?

1 Min Read How Does Sunlight Affect Immunity?